107 related articles for article (PubMed ID: 12127710)
1. Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model.
Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH; Firsov AA
Int J Antimicrob Agents; 2002 Jul; 20(1):44-9. PubMed ID: 12127710
[TBL] [Abstract][Full Text] [Related]
2. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
Firsov AA; Vasilov RG; Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH
J Antimicrob Chemother; 1999 Apr; 43(4):483-90. PubMed ID: 10350376
[TBL] [Abstract][Full Text] [Related]
3. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities.
Firsov AA; Vostrov SN; Shevchenko AA; Portnoy YA; Zinner SH
Antimicrob Agents Chemother; 1998 Nov; 42(11):2841-7. PubMed ID: 9797213
[TBL] [Abstract][Full Text] [Related]
4. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.
Firsov AA; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
Antimicrob Agents Chemother; 1999 Mar; 43(3):498-502. PubMed ID: 10049257
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
[TBL] [Abstract][Full Text] [Related]
6. Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships.
Zinner SH; Vostrov SN; Lubenko IY; Portnoy YA; Cornaglia G; Firsov AA
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):167-71. PubMed ID: 11576789
[TBL] [Abstract][Full Text] [Related]
7. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept.
Firsov AA; Shevchenko AA; Vostrov SN; Zinner SH
Antimicrob Agents Chemother; 1998 Mar; 42(3):659-65. PubMed ID: 9517948
[TBL] [Abstract][Full Text] [Related]
8. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses.
Firsov AA; Zinner SH; Lubenko IYu ; Vostrov SN
Int J Antimicrob Agents; 2000 Dec; 16(4):407-14. PubMed ID: 11118849
[TBL] [Abstract][Full Text] [Related]
9. MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model.
Firsov AA; Vostrov SN; Shevchenko AA; Zinner SH; Cornaglia G; Portnoy YA
Antimicrob Agents Chemother; 1998 Nov; 42(11):2848-52. PubMed ID: 9797214
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio.
Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH; Firsov AA
Antimicrob Agents Chemother; 2000 Apr; 44(4):879-84. PubMed ID: 10722485
[TBL] [Abstract][Full Text] [Related]
11. Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model.
Portnoy YA; Vostrov SN; Lubenko IY; Zinner SH; Firsov AA
Int J Antimicrob Agents; 2002 Sep; 20(3):201-5. PubMed ID: 12385699
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
[TBL] [Abstract][Full Text] [Related]
13. Pseudomonas aeruginosa in vitro corneal isolate sensitivity to ofloxacin, ciprofloxacin, and trovafloxacin: a comparative study.
Song A; McCulley TJ; Lam BL; Feuer WJ; Miller D; Alfonso EC
Am J Ophthalmol; 2001 Jun; 131(6):795-6. PubMed ID: 11384579
[TBL] [Abstract][Full Text] [Related]
14. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
Madaras-Kelly KJ; Ostergaard BE; Hovde LB; Rotschafer JC
Antimicrob Agents Chemother; 1996 Mar; 40(3):627-32. PubMed ID: 8851583
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa.
McNabb J; Quintiliani R; Nightingale CH; Nicolau DP
Chemotherapy; 2000; 46(6):383-9. PubMed ID: 11053903
[TBL] [Abstract][Full Text] [Related]
16. Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers.
Prieto J; Aguilar L; Fuentes F; Giménez MJ; Alou L; Dal-Ré R; Sörgel F; Frías J
Int J Antimicrob Agents; 2001 Sep; 18(3):231-8. PubMed ID: 11673035
[TBL] [Abstract][Full Text] [Related]
17. The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses.
Zinner SH; Firsov AA; Gilbert D; Simmons K; Lubenko IY
J Antimicrob Chemother; 2001 Dec; 48(6):821-6. PubMed ID: 11733466
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of trovafloxacin against ciprofloxacin-susceptible and -resistant clinical bacterial isolates and assessment of the trovafloxacin disk test.
Fuchs PC; Barry AL; Brown SD
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):33-8. PubMed ID: 9990473
[TBL] [Abstract][Full Text] [Related]
19. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
Burgess DS; Hastings RW
Diagn Microbiol Infect Dis; 2000 Sep; 38(1):37-41. PubMed ID: 11025182
[TBL] [Abstract][Full Text] [Related]
20. Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones.
Firsov AA; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
Antimicrob Agents Chemother; 2005 Jul; 49(7):2642-7. PubMed ID: 15980331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
